Studies have shown that targeting CA IX with CAR-T cells in metastatic RCC patients can result in “on-target” toxicity, and pre-treatment with CA IX monoclonal antibodies can effectively prevent hepatotoxicity and increase the tolerated dose of CAR-T cells. The gene discussed is CA9; the disease is renal cell carcinoma.